Pediatric Infectious Disease

Register      Login

VOLUME 3 , ISSUE 3 ( July-September, 2021 ) > List of Articles

Immunology Corner

Is Early-onset Inflammatory Bowel Disease a Primary Immune Deficiency?

Rachna Shanbhag

Keywords : Inflammatory bowel disease, Primary immune deficiency disease, Very early-onset IBD

Citation Information : Shanbhag R. Is Early-onset Inflammatory Bowel Disease a Primary Immune Deficiency?. Pediatr Inf Dis 2021; 3 (3):125-127.

DOI: 10.5005/jp-journals-10081-1310

License: CC BY-NC 4.0

Published Online: 25-01-2022

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Pediatric-onset IBDs (PIBDs) are a group of genetically heterogeneous diseases with variable severity. Depending on the age of onset, inflammatory bowel disease (IBD) can be classified as pediatric-onset (<17 years), early-onset (<10 years), very early-onset (<6 years), infant/toddler-onset (0–2 years), and neonatal-onset IBD (<28 days). Due to the advancement of molecular science and sequencing technologies, several monogenic defects have been identified in very early-onset IBD (VEO-IBD) over the last few decades. Inflammatory bowel disease manifesting at a very young age is more likely to be a monogenic defect. Pediatric-onset IBDs have been found to be associated with as many as 60 monogenic defects with most presenting below 6 years of age and some presenting before 1 year of age. The current article discusses early-onset IBD in detail with new concepts and a clinical and laboratory approach to these patients has been provided.

PDF Share
  1. Stein RE, Baldassano RN. Inflammatory bowel disease. In: St Geme K, Blum S, Tusker W, et al. Nelson textbook of pediatrics. 21st ed., vol. 1, Philadelphia: Elsevier; 2020. p. 1986.
  2. Sýkora J, Pomahačová R, Kreslová M, et al. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol 2018;24(25):2741. DOI: 10.3748/wjg.v24.i25.2741.
  3. Shim JO. Recent advance in very early onset inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr 2019;22(1):41–49. DOI: 10.5223/pghn.2019.22.1.41.
  4. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflammat Bowel Dis 2011;17(1):423–439. DOI: 10.1002/ibd.21349.
  5. Doecke JD, Simms LA, Zhao ZZ, et al. Genetic susceptibility in IBD: overlap between ulcerative colitis and Crohn's disease. Inflammat Bowel Dis 2013;19(2):240–245. DOI: 10.1097/MIB.0b013e3182810041.
  6. Paul G, Khare V, Gasche C. Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Investigat 2012;42(1):95–109. DOI: 10.1111/j.1365-2362.2011.02552.x.
  7. Eastaff-Leung N, Mabarrack N, Barbour A, et al. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010;30(1):80–89. DOI: 10.1007/s10875-009-9345-1.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.